Your post is positive so let me get you some fine tuning : 1. There is no % measurement in preclinical efficacy study - which is not conducted on human beings but on human tissues so there for it cannot measure any percentage . The reduction of sizable amount of biological inflammation markers related to psoriasis IS THE BIG BREAKTHROUGH ! So far no one was able such and this is what the preclinical studies are all about . The fact that the company is not making BS statements is because they care about us , the investors , and want to stay transparent and accurate 2. People are looking at the last Q representing the Quarter ended on 9/30/16 and throwing BS. At that time the company was RAISING money and now the company HAVE money ( over 2mm$ and no convertibles notes - so no toxic dilution is expected). 3. Kodiak or its assignee "old nation " have 0 shares . They dumped it to the market already in September 2016 The fact